Red Skin Syndrome Blog

/Red Skin Syndrome Blog/

Curiouser and Curiouser – Part 3

By | August 18th, 2017|Topical Steroid Withdrawal|

Scientific misinformation and disinformation is a crime against the patient. The NEA and their paid minions including ITSAN continue to disinform the public and perform dishonorable work that harms patients. They have chosen to ignore 35 years of my own published papers, lectures, websites, essays, and cured patients proving that complete and total withdrawal from [...]

Curiouser & Curiouser – Part 2

By | August 16th, 2017|Topical Steroid Withdrawal|

The curiouser part unfolds as we examine the lecture - never given before in 30 years - that recommends steroids need to be handled, applied, tapered, and used very carefully. There is no mention of my 35 years of clinical observations concerning addiction to corticosteroids. The information that withdrawal from corticosteroids is the cure for [...]

Curiouser & Curiouser – Part 1

By | August 14th, 2017|Topical Steroid Withdrawal|

The National Eczema Association (NEA) has adopted an Alice in Wonderland approach to steroid addiction. The NEA recently advertised a free webinar presentation to be viewed on August 23rd. The RN spokesperson will discuss how to “safely” start and taper off steroids. After 30 years of nonstop steroid advocacy, their published papers stating that addiction [...]

How Many More Therapies Are Needed for “Bad Eczema?” NONE

By | July 24th, 2017|RSS|

When is enough enough? Apparently Never for Big-Pharma. I have counted 11 useless therapies for the non-entity “bad eczema.“ These patients do not have “bad eczema” they are misdiagnosed Red Skin Syndrome (RSS) sufferers. Cure is already available but a curative treatment is only possible with a correct diagnosis. RSS patients are constantly and consistently [...]

Why More Studies?

By | July 19th, 2017|Red Skin Syndrome, Red Skin Syndrome Cures, RSS Patients|

A cured steroid addicted RSS patient forwarded the most recent advertisement from ITSAN to me. It is a call for patients to sign on to a study of RSS patients in Australia. It must be clarified for ITSAN that in appropriate medical parlance you do studies and lab tests when you do not have an [...]

New Ideas

By | June 26th, 2017|Uncategorized|

Dr. John Sarno, 93, Dies; Best-Selling Author Tied Pain to Anxieties. Like anyone in medicine, he did not have ALL the answers, but he had many. He is a true champion who listened to his patients, learned from them, and helped others because of them. He left the basic science research to others who proved [...]

Eucrisa – A New Cream For Eczema

By | April 19th, 2017|RSS|

A new topical medication, Eucrisa, for treating eczema has recently been approved by the FDA. With keen interest I read every word of the backup study and publication in the Journal of the American Academy of Dermatology concerning then named Opa-15406, a novel topical non-steroidal PDE4 inhibitor. The study included patients who had just recently [...]

Academy Of Dermatology Poster

By | April 17th, 2017|RSS Patients|

A physician, Tim Berger, presented a poster at the recent March, 2017, Academy of Dermatology meeting. In essence he implies that he discovered TSA, TSW and RSS with the caveat that these patients itch. It is evident that he never saw any of the patients, since this was only a survey from the internet. The [...]

Dupilumab Study – Subject Patient Comments

By | April 6th, 2017|Dupilumab|

The Dupilumab studies were 16 weeks long. This is a very short time to truly evaluate a drug in this very difficult and prolonged skin problem. In addition, there were no objective comments on rash, redness, skin oozing, edema and pain. There are no long term follow ups reported. But: Links to patient comments after [...]

Dupilumab Study – Are Eczema Patients Being ‘duped’ Again?

By | April 4th, 2017|Dupilumab|

My most recent postings have dissected the protocol, the patients, the methods and the fine print of the Dupilumab studies reported in the medical literature. Severe failings are evident in all the above criteria. What, therefore can we expect from the results and conclusions? This assessment will group together all Dupilumab studies. My findings are: [...]